Abstract Library

#4663 CAREFNDR: A phase III, randomised, parallel group, placebo-controlled study to evaluate the efficacy and safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumours

Introduction: Paltusotine is a once-daily, oral, nonpeptide, selective SST2 receptor agonist in development for carcinoid syndrome (CS) treatment. In a Phase 2, open-label, dose-ranging study, paltusotine reduced the frequency and severity of CS symptoms and was well tolerated (NCT05361668).

Conference:

Presenting Author:

Authors: Kim R, Usiskin K, Fan X, Quock T, Mui C,

Keywords: paltusotine, phase 3 trial, somatostatin receptor agonist, neuroendocrine tumour, carcinoid syndrome,

#4567 Malignant pheochromocytoma with late distant metastases and secondary hypercalcaemia

Introduction: Pheochromocytoma is a rare neuroendocrine tumour of the adrenal medulla. Malignant variants occur with a very low frequency and can be diagnosed only after the spread of distant metastasis.

Conference:

Presenting Author:

Authors: Kirova I, Vandeva S, Markova M, Elenkova A, Robeva R,

Keywords: neuroendocrine, malignant pheochromocytoma, metastasis, hypercalcaemia,

#4548 Carcinoid heart disease in patients with carcinoid syndrome and metastatic small intestinal neuroendocrine tumours: A single centre experience

Introduction: Carcinoid heart disease (CHD) is a significant complication of carcinoid syndrome (CS) in patients with small intestinal neuroendocrine tumours (SINET). Management is complex and more data is needed.

Conference:

Presenting Author:

Authors: Salman M, Waters M, Abbott C, Quinn M, O'Toole D,

Keywords: carcinoid heart disease, carcinoid syndrome, NET, neuroendocrine tumour, small intestinal NET,

#4472 Paraneoplastic cerebellar degeneration relates to lung neuroendocrine tumour

Introduction: Neurological Paraneoplastic syndromes related to cancer are infrequently,

Conference:

Presenting Author:

Authors: González Devia D, Roa Culma L, Martínez Rubio C, Zafra Sierra M, Cañon Solano D,

Keywords: Paraneoplastic Syndrome, Paraneoplastic Cerebellar Degeneration, Neuroendocrine Tumour, Lung Neuroendocrine Tumour, CARP 8 antibody,

#4418 Endoscopic ultrasound-guided radiofrequency ablation is a safe and efficient treatment of symptomatic insulinomas – A single centre experience of 14 patients

Introduction: The vast majority of insulinomas are benign and less than 20 mm. Surgery is considered as standard treatment, but complications are significant. Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) represents a novel and minimally invasive approach.

Conference:

Presenting Author: Andreassen M

Authors: Andreassen M, Kovacevic B, Brink L, Hansen C, Knigge U,

Keywords: Insulinoma, Benign, EUS, radiofrequency ablation,